Pixium Vision - Signalling an intent to access US investors
Pixium provided a minor business update on 2 June, indicating that it is seeking to capitalise on increased interest from US investors in recent months and that it has hired a US investment bank to advise on possible options, including a mechanism to list on the Nasdaq. The core operational focus remains on advancing the Prima Bionic Vision system (BVS) through the ongoing PRIMAvera pivotal EU study, with top-line data now guided for early 2023 (from late 2022 previously), with a potential European launch in late 2023. We have slightly pushed back our commercialisation forecasts and moderated our pricing assumptions, resulting in a new rNPV of €122.5m.Pixium Vision SA is a company that specializes in sensorial neuromodulation. Co. is also collaborating with scientific groups and clinicians at research institutes and clinical centers around the world, including Stanford University (USA). Co. is developing and aims to commercialize Bionic Vision Systems (BVS) – namely active implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.